Navigation Links
Merrimack Pharmaceuticals' Preclinical Research Shows MM-121 Restores Sensitivity to Anti-Estrogen Therapy and Delays Onset of Treatment Resistance in ER-Positive Breast Cancer Model
Date:4/8/2013

CAMBRIDGE, Mass., April 8, 2013 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced preclinical study results showing that the novel therapy MM-121 restores tumor sensitivity and delays the onset of resistance to the aromatase inhibitor, letrozole, in an ER+ breast cancer model. The study was presented as part of the American Association for Cancer Research's 2013 Annual Meeting in Washington, DC, April 6-10, 2013.

MM-121 is a fully human monoclonal antibody that targets ErbB3, a cell surface receptor implicated in tumor growth and survival. By inhibiting ErbB3 signaling, MM-121 was found to restore sensitivity, delay resistance and enhance the anti-tumor effect of letrozole as a combination therapy partner.

"In nearly all cases of advanced ER+ breast cancer, endocrine therapies are initially effective, but patients eventually develop resistance to these treatments," said Gavin MacBeath , Co-Founder and Head of Translational Research, Merrimack Pharmaceuticals. "We are excited to see that in preclinical models, MM-121 blocked activation of its target, ErbB3, and down-regulated several signaling pathways within these tumors.  We saw delayed resistance to letrozole when co-administered with the drug, and restored sensitivity when added after the tumors developed resistance to letrozole. These data help guide our thinking regarding how best to combine MM-121 with anti-hormonal therapies in the treatment of advanced ER+ breast cancer."

Study Methodology
The activity of MM-121 alone and in combination with letrozole was measured in an MCF7 in vivo model of post-menopausal ER+ breast cancer engineered to express aromatase. Models of ER+ breast cancer were randomized to receive letrozole, MM-121 or both MM-121 and letrozole following development of resistance to letrozole. Tumor
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor
2. Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer
3. scPharmaceuticals LLC Announces Strategic Partnership with Sensile Medical to Develop Novel Heart Failure Treatment Aimed to Reduce Readmission Rates
4. Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD334 for Autoimmune Diseases
5. Covis Pharmaceuticals, Inc Named US Distributor For Five Additional Products
6. Vanda Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
7. Regeneron Pharmaceuticals Announces Expansion in New Yorks Hudson Valley
8. Valeant Pharmaceuticals Provides Update to Recent Event
9. Oramed Pharmaceuticals Granted Japanese Patent for its Core Technology in Oral Delivery of Proteins
10. Valeant Pharmaceuticals And Obagi Medical Products Agree On An Increased Offer Price Of $24.00 Per Share In Cash
11. European Nuclear Medicine / Radiopharmaceuticals Market Worth by Reach $1.6 Billion by 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 2015 Research and Markets ... of the "Lab Accessories Market by ... Station) & End User (OEM/Biotechnology & Pharmaceutical ... 2020" report to their offering. ... expected to reach $504.7 million by 2020 ...
(Date:4/24/2015)... Company, Inc. (NYSE: LCI ) today announced that ... facility to $120 million from $50 million.  The amended ... company to increase borrowings by a total of up ... commitments from existing lenders or new lending institutions.  The ... 2018.   "The amended credit facility, together ...
(Date:4/23/2015)... CHICAGO, Ill. , April 24, 2015  AbbVie ... Food and Drug Administration (FDA) has accepted its New ... company,s, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, ... for the treatment of adults with chronic genotype 4 ... regimen is the first all-oral, interferon-free therapy being evaluated ...
Breaking Medicine Technology:Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 2Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 3Lannett Expands Revolving Credit Facility To $120 Million 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7
(Date:4/25/2015)... 2015 Carinsurancequotesinfo.com has released a new ... cost auto insurance for flatbed trucks. , ... sometimes other vehicles. They are mainly used for commercial ... released blog post explains that by comparing multiple offers, ... and other commercial vehicles. , It is now possible ...
(Date:4/25/2015)... Islands, BWI (PRWEB) April 25, 2015 ... has celebrated three months of successfully welcoming visitors to ... 5, 2015. , As part of a major ... Providenciales airport was completely redesigned to speed up arrivals. ... the process of getting out of the airport and ...
(Date:4/25/2015)... York New York (PRWEB) April 25, 2015 ... that Dr. Jerry Blaivas has been chosen by the New ... for his contributions to medicine in the field of Urology. ... the best in his speciality, Genito-Urinary diseases. He was ... specifically in the field of urology. Not only did ...
(Date:4/25/2015)... 2015 For thirteen years, the Twin Cities ... education event in the nation! This year, on May 5th, ... US to take DI Day on the road by supporting ... CLU, ChFC, RHU, DIA, CLTC, Chief Executive Officer at Secura ... on the change by stating, "The first Twin Cities DI ...
(Date:4/24/2015)... 24, 2015 Multi Customer Discount , ... pumping ( http://www.zeitersseptics.com/multi-customer-discount.html ) of 1000-1500 gallons in Zeiter's ... program. This does not include any Dig fees, or ... per person. If someone is part of this group ... totaling approximately 2500 gallons or more, the cost would ...
Breaking Medicine News(10 mins):Health News:Auto Insurance Quotes for Flatbed Trucks Available Online! 2Health News:The Tuscany on Grace Bay Celebrates Providenciales Airport Expansion With Summer Specials to Travelers! 2Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 2Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 3Health News:Secura Consultants Takes DI Day On The Road 2Health News:Zeiter's Septics Inc. Offers Multi Customer Septic Tank Cleaning Program in Cook, Putnam & Will Counties in May 2015 2Health News:Zeiter's Septics Inc. Offers Multi Customer Septic Tank Cleaning Program in Cook, Putnam & Will Counties in May 2015 3
... Qiao Xing,Mobile Communication Co., Ltd. (,Qiao Xing Mobile, or ... domestic manufacturers of mobile,handsets through its subsidiary CEC Telecom ... C7000A cardiograph mobile handset., The C7000A has ... will be able to perform a basic ...
... form of breast cancer are being tested in a ... six continents -- a clinical trial that investigators hope ... This trial, dubbed ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment ... initiatives in which two large, academic breast cancer research ...
... affected by ... rare diseases, NEW YORK, Feb. ... Day will be launched on Friday 29,February...because it,s a rare day that ... Shire plc at:, http://media.medialink.com/WebNR.aspx?story=34701 ), Collectively, rare diseases aren,t ...
... Firm,s Growing Healthcare Practice, BROOKFIELD, Wis., Feb. ... human resources outsourcing company, has added,Gordon Warner to ... Services,Director., Warner brings extensive HR experience and ... Warner comes to Pinstripe from,M&I Bank in Milwaukee, ...
... 28 Millennium,Pharmaceuticals, Inc. (Nasdaq: MLNM ... 2008 Susquehanna Healthcare Conference will be webcast ... Investors section of the Company,s website, http://www.millennium.com ... The presentation will include an overview ...
... Idaho, Feb. 28 NightHawk,Radiology Holdings, Inc. (Nasdaq: ... groups across the United States, today announced,that Ernest G. ... of the,company,s Board of Directors for personal reasons. Mr. ... company intends to immediately begin a search,to identify a ...
Cached Medicine News:Health News:Qiao Xing Mobile's CECT Subsidiary Releases Newest Handset Model; C7000A Offers Cardiograph, 120 Days Ultra-Long Standby and 3.0'' LCD Screen 2Health News:Qiao Xing Mobile's CECT Subsidiary Releases Newest Handset Model; C7000A Offers Cardiograph, 120 Days Ultra-Long Standby and 3.0'' LCD Screen 3Health News:New study of targeted therapies for breast cancer -- model for global clinical trials 2Health News:New study of targeted therapies for breast cancer -- model for global clinical trials 3Health News:New study of targeted therapies for breast cancer -- model for global clinical trials 4Health News:VIDEO from Medialink and Shire plc: Rare Diseases Must Be Top of the Health Agenda 2Health News:VIDEO from Medialink and Shire plc: Rare Diseases Must Be Top of the Health Agenda 3Health News:Pinstripe Healthcare Group Adds Veteran HR Executive Warner as Client Services Director 2Health News:2008 Susquehanna Healthcare Conference to Webcast Millennium Presentation 2Health News:NightHawk Radiology Holdings, Inc. Announces Board Member Departure 2
... Exp Expandable Tip System A lower cost ... you to perform multi-sample transfers between two different ... a knob, tip spacing can be quickly and ... or 96 well plates. Ergonomic Design for ...
... Tip System A lower cost alternative to ... perform multi-sample transfers between two different vessel configurations. ... tip spacing can be quickly and easily adjusted ... well plates. Ergonomic Design for Unparalleled Comfort ...
... A lower cost alternative to Equalizers, the patented ... between two different vessel configurations. With the push ... be quickly and easily adjusted for test tubes ... Ergonomic Design for Unparalleled Comfort Pick one ...
... Exp Expandable Tip System A lower ... allows you to perform multi-sample transfers between two ... of a knob, tip spacing can be quickly ... tubes) or 96 well plates. Ergonomic Design ...
Medicine Products: